We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Cerebrolysin
An injectable neuropeptide preparation made from enzymatically digested pig (porcine) brain tissue — a mix of low-molecular-weight peptides and free amino acids marketed as a neurotrophic agent for stroke, dementia and traumatic brain injury. It is approved and widely used in Russia, China and parts of Europe/Asia, but is NOT FDA-approved. Honest appraisal: the highest-quality syntheses contradict the marketing. The Cochrane review of acute ischaemic stroke found no benefit on death or function and a possible harm signal (more non-fatal serious adverse events); the Cochrane review of vascular dementia rated the evidence very-low-quality and warned any benefit may be too small to matter. Many positive trials and meta-analyses are industry-funded and heterogeneous.
Prescription medication — not a dietary supplement
Cerebrolysin is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Cerebrolysin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1990–2026 with a typical study size of 143 participants.
Based on 83 studies · 15 meta-analyses · 61 RCTs · 9,818 total participants
Confidence
High confidenceBy outcome
Despite many meta-analyses, the highest-quality Cochrane reviews find no stroke benefit (with a possible harm signal) and only very-low-quality dementia evidence, while positive trials are industry-linked, holding the score emerging.
90 rigorous studies
61 randomized trials · 19 meta-analyses · 19 systematic reviews
Our evidence rating for Cerebrolysin is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
8 trials ongoing or recruiting · 19 completed on ClinicalTrials.gov
3 of the completed trials have posted results
Registered trials show research momentum for Cerebrolysin, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Cerebrolysin is a peptidergic drug produced by the controlled enzymatic breakdown of purified pig (porcine) brain proteins, yielding a mixture of low-molecular-weight neuropeptides and free amino acids.
It is given by intramuscular injection or, at higher doses, intravenous infusion, and is promoted as a 'neurotrophic' / 'neuroprotective' agent — the idea being that its peptides mimic endogenous neurotrophic factors (BDNF/GDNF-like activity) to support neuronal survival and neuroplasticity.
It has been approved and is heavily used for decades in Russia, China, and a number of European, post-Soviet and Asian countries for acute ischaemic stroke, vascular and Alzheimer's dementia, and traumatic brain injury.
It is NOT approved by the US FDA and is not a dietary supplement; it is a biological injectable drug, and any non-prescription/grey-market sourcing carries real sterility and identity risks for a pig-tissue-derived product.
The honest evidence picture is mixed-to-disappointing once the highest-quality syntheses are weighed.
The 2020 Cochrane review of acute ischaemic stroke (7 RCTs, 1601 participants) found Cerebrolysin probably makes little or no difference to all-cause death and concluded there was no demonstrated clinical benefit — while flagging moderate-quality evidence of an INCREASE in non-fatal serious adverse events (RR 2.15, 95% CI 1.01-4.55), more pronounced at the higher 30 mL dosing schedule.
The 2019 Cochrane review of vascular dementia (6 RCTs, 597 participants) found a possible cognitive/global-function signal but rated the evidence very-low-quality, noted all the studies had high risk of bias and most were industry-supported, and cautioned that any real effect may be too small to be clinically meaningful.
Against this sit a series of largely industry-linked positive trials and meta-analyses: the CARS / CARS-1+CARS-2 stroke-rehabilitation trials and the CAPTAIN TBI trials report small-to-medium benefits on motor and functional scales; a 2015 meta-analysis suggested benefit in mild-to-moderate Alzheimer's; and TBI meta-analyses report improved GCS/GOS but no mortality benefit.
Even some positive TBI RCTs miss their primary endpoint (a 2023 three-arm rTMS + Cerebrolysin trial showed only non-significant descriptive trends).
The result is a genuinely mixed body of evidence in which the most rigorous, least-conflicted analyses are null-to-negative for the headline indication (acute stroke) and only weak for dementia. Overall evidence is therefore Emerging.
Cerebrolysin is a mixture of porcine-brain-derived neuropeptides and amino acids said to have properties resembling endogenous neurotrophic factors (e.g. BDNF/GDNF), proposed to support neuronal survival and growth. This is the marketed rationale; it is characterised mainly in preclinical work.
Proposed to limit secondary injury cascades (excitotoxicity, neuroinflammation, apoptosis) and to promote neuroplasticity/neurorecovery after ischaemic or traumatic brain injury. Mechanistic claims outrun the human efficacy data, which are mixed.
How Cerebrolysin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
The highest-quality synthesis (Cochrane) shows no benefit and a possible increase in non-fatal serious adverse events — weigh this against the marketing claims.
Not adequately studied — avoid.
Listed as a labelling caution; use only under specialist supervision.
Do not. It is a pig-brain-derived injectable biological; unverified product carries sterility, identity and contamination risk and is not FDA-approved.
Product labelling cautions against combining with MAO inhibitors and certain antidepressants because of additive/summation effects; use only under medical supervision.
Labelling advises against co-administration in the same infusion with balanced amino-acid solutions; an injectable drug to be handled clinically, not stacked like a supplement.
Tip: Cochrane found a possible increase in non-fatal serious adverse events in acute ischaemic stroke, more pronounced at the higher 30 mL schedule — a reason for caution, not a benign profile.
Tip: Administer by a clinician; rotate sites.
Tip: Often linked to too-rapid infusion; slow administration.
Tip: Stop immediately; seek medical care. Risk is inherent to an animal-tissue-derived injectable.
Cerebrolysin has an evidence score of 4/10 — emerging evidence based on 77 indexed studies, including 7 meta-analyses. An injectable neuropeptide preparation made from enzymatically digested pig (porcine) brain tissue — a mix of low-molecular-weight peptides and free amino acids marketed as a neurotrophic agent for stroke, dementia and traumatic brain injury. It is approved and widely used in Russia, China and parts of Europe/Asia, but is NOT FDA-approved. Honest appraisal: the highest-quality syntheses contradict the marketing. The Cochrane review of acute ischaemic stroke found no benefit on death or function and a possible harm signal (more non-fatal serious adverse events); the Cochrane review of vascular dementia rated the evidence very-low-quality and warned any benefit may be too small to matter. Many positive trials and meta-analyses are industry-funded and heterogeneous. Representative study: PMID 37818733.
The commonly studied dose of Cerebrolysin is Trial regimens vary widely (e.g. 30 mL/day IV for 10-21 days in stroke/dementia; intramuscular injection at lower doses). No validated optimal dose; this is a prescription drug abroad, not a self-administered supplement.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Cerebrolysin is in the morning. It can be taken on an empty stomach. Administered by injection (intramuscular at lower doses, intravenous infusion at higher doses) in daily treatment courses (commonly 10-21 days) under medical supervision in the countries where it is approved.
Cerebrolysin should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are non-fatal serious adverse events (acute stroke setting), injection-site reactions, agitation / feeling hot / sweating / dizziness. Use caution if any of these apply to you: Known hypersensitivity to the product (porcine-derived biological); Severe renal impairment (status epilepticus and epilepsy are listed cautions in product labelling); Pregnancy / breastfeeding (not adequately studied).
Creatine
Likely helpsIncreases phosphocreatine stores for faster ATP regeneration, boosting strength, power output, and cognitive function under stress.
Omega-3
Probably helpsEssential fatty acids critical for brain health, mood regulation, and reducing inflammation throughout the body.
Acetyl-L-Carnitine
Likely helpsAcetylated carnitine that crosses the blood-brain barrier to fuel mitochondrial energy and donate acetyl groups for acetylcholine synthesis.
Alpha-GPC
Likely helpsCrosses the blood-brain barrier to fuel acetylcholine synthesis — supports focus, memory, and power output in athletes.
Explore: Best supplements for Focus, Memory & Mood
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 83 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research